Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence
The takeover, which includes the candidate felzartamab, for immune-mediated diseases, diversifies Biogen’s scope.
04 July 2024
04 July 2024
The takeover, which includes the candidate felzartamab, for immune-mediated diseases, diversifies Biogen’s scope.
Advances in automation in T-cell production are beginning to help make life-changing therapies more accessible to a growing number of patients in oncology and beyond.
CureVac is entitled to receive an upfront payment of €400m and milestone payment of €1.05bn from GSK.
The company will reduce its workforce by 30% to extend its financial runway to 2028.
The initiative will build capacity in low and middle-income countries for producing mRNA vaccines and therapeutics.
Dupixent's approval is supported by findings from the Phase III BOREAS and NOTUS studies.
Leqembi and Kisunla could generate global sales of $3.5 billion and $2 billion respectively by 2030.
The new antibody aims to promote the destruction of cancer cells by macrophages.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.